Background: Subacute stent thrombosis (SAT) is a rare but devastating complication of intracoronary stent implantation. The incidence with potent anti-platelet therapy has been reported to be between 0.5-1.9%. Recently, the sirolimus-eluting Cypher™ stent was introduced in the US. The randomized SIRUS trial reported a 0.4% rate of SAT. However, the Food and Drug Administration has received 47 reports of SAT that occurred in clinical practice and the manufacturer has subsequently issued a warning letter. The aim of this study was to evaluate the incidence and potential risk factors of SAT in patients receiving the sirolimus-eluting stent outside of clinical trials. Methods: Since the commercial introduction of Cypher™ stents to the US in April 2003, all patients that received sirolimus-eluting stents at our institution were followed in a registry. Percutaneous coronary intervention was performed using standard techniques. All patients were treated with aspirin pre-and clopidogrel or ticlopidine immediately postprocedure. The primary endpoint of the study was the incidence of SAT at 30 days. Results: A total of 456 patients underwent implantation of 608 sirolimus-eluting stents. The mean stent diameter was 2.8±0.3 mm and the mean stent length was 19.7±5.7 mm. There were no cases of SAT during the index hospitalization, with 4 cases reported after discharge during the first 30 days post-stenting (mean onset 9±4 days). There was no apparent difference in stent diameter (2.6±0.2 mm) or stent length (19.7±6.1 mm) between patients with SAT and the rest of the population. Three of the 4 patients discontinued anti-platelet therapy after hospital discharge and in one patient the sirolimus-eluting stent was implanted in the setting of an acute myocardial infarction. Conclusion: Even in 'real world' patients, the incidence of SAT after sirolimus-eluting stent implantion is less than 1%, and within the expected range for bare metal stents. The discontinuation of anti-platelet therapy appears to be the most important risk factor for the development of SAT.
Background:The true incidence of early stent thrombosis after sirolimus or paclitaxel-eluting stent (PES) implantation in an unselected group is at present controversial. So far, there has been no systematic collection of data to examine its true incidence in the realworld setting. Aim: To compare the real-world, tertiary referral institution incidence of angiographic stent thrombosis in both sirolimus-eluting stents (SES) and PES with historical controls. Method: Since April 2002, drug eluting stents (DES) have been the default strategy in patients undergoing percutaneous coronary intervention at our institution. 1000 consecutive patients treated with SES and 500 consecutive patients treated with PES were defined as our sample population. The last 500 consecutive patients exclusively treated with bare stents form our control group. Clopidogrel use was as follows: at least one month following bare stent implantation, at least 3 months following SES implantation, and at least 6 months following PES implantation. Early stent thrombosis is defined as stent thrombosis occurring < 30 days after stent implantation. Results: In our cohort, the incidences of early stent thrombosis are as follows:
Conclusion: This is the first study to demonstrate that both SES and PES are safe and are comparable to historical bare stent controls in the real world population of unselected patients. There appears to be no statistical difference in the incidence of early stent thrombosis in both DES groups. Background: Drug eluting stents (DES) have been shown to have very low restenosis across a range of lesion subtypes. We tested the hypothesis that their implementation would permit a cost effective percutaneous approach to a majority of patients with multivessel disease. Methods: Two experienced interventionalists reviewed the preoperative coronary angiograms of 209 patients undergoing their first coronary bypass operation (CABG) for multivessel disease without other adjunctive surgical procedures at the Royal Brompton Hospital in 2002. They were classified according to the technical feasibility and completeness of percutaneous revascularisation (PCI) and a provisional strategy was declared. A cost decision-analysis model with simulated 1 year costs was constructed with a cost of DES at $3,360. Results: Mean age was 64.6±8.9 years with 54 diabetics (25.8%). Each patient received at least 1 arterial graft and a mean of 3.0±0.8 distal anastomoses. Mean post-CABG stay was 8.9±7.2 days and total cost $22,653. Adequate PCI was judged to be unachievable in the presence of at least 1 unfavourable total occlusion (CTO) (excessive length, unfavourable take-off, poor visualisation of the distal vessel) subtending viable myocardium in 48 patients (23%) and extreme tortuosity or calcification in 4 patients (2%). PCI of grafted major epicardial vessels was anticipated to be complete in 138 patients (66%) and partial but acceptable in 19 patients (9.1%). Stenting of the left main, "favourable" CTO, bifurcations or in an ostial location were required in 32 (20.4%), 60 (38.2%), 77 (49.0%) and 74 (47.1%) respectively of cases treated. 3.6±1.4 stents of total length 72.6±37.3 mm were required to treat 3.3±1.2 lesions per patient at an estimated cost of $22,206. One year repeat revascularisation at an assumed rate of 15% in the PCI group resulted in a $2,250 cost excess for PCI. Conclusions: PCI is feasible for a majority of patients undergoing multivessel CABG with marginally lower hospital cost ($446). It demands however, the use of multiple long stents and frequent treatment of challenging lesion subtypes. At current DES cost, PCI is likely to remain more expensive than CABG during long term follow up.
Incidence of Early Stent Thrombosis
Bare stent SES PES p value Incidence 5/ 500 9/ 1000 5/ 500 Percentage 1.0% 0.9% 1.2% p=0.9
